Figure 1.
Management of heart failure with preserved ejection fraction. (A) Benefits of novel weight- and glucose-lowering pharmacotherapies combined with exercise training. (B) Risk management of potential drug-induced sarcopenia with exercise training. HFpEF, heart failure with preserved ejection fraction; GLP-1, glucagon-like peptide-1 receptor agonist; SGLT2 inhibitor, sodium–glucose cotransporter 2 inhibitors